A shutter shock image file of 131812463 with dna like image
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
GALVESTON, Texas, Feb. 7, 2017 /PRNewswire/ -- Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases (NIH-NIAID) to develop TP508 as a countermeasure…